|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||
| Current assets: | |||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||
| Prepaid expenses | |||||||||||||||||
| Prepaid expenses- related party | |||||||||||||||||
| Accounts receivable | |||||||||||||||||
| Restricted cash | |||||||||||||||||
| Prepaid expenses and other current assets | |||||||||||||||||
| Total current assets | |||||||||||||||||
| Deferred tax asset | |||||||||||||||||
| Cash and investments held in Trust Account | |||||||||||||||||
| Property and equipment, net | |||||||||||||||||
| Operating lease right-of-use asset, net | |||||||||||||||||
| Capitalized software, net | |||||||||||||||||
| Total assets | |||||||||||||||||
| Liabilities and Stockholders’ Deficit | |||||||||||||||||
| Current liabilities: | |||||||||||||||||
| Accounts payable | |||||||||||||||||
| Franchise tax payable | |||||||||||||||||
| Accrued expenses | |||||||||||||||||
| Due to related party | |||||||||||||||||
| Accounts payable and accrued expenses | |||||||||||||||||
| Forward purchase derivative liabilities | |||||||||||||||||
| Forward purchase derivative liabilities | |||||||||||||||||
| Tranche right derivative liabilities (Tranche Rights) | |||||||||||||||||
| Total forward purchase derivative liabilities | |||||||||||||||||
| Convertible debt | |||||||||||||||||
| Convertible 12% promissory notes | |||||||||||||||||
| 2024 convertible promissory notes | |||||||||||||||||
| Convertible Promissory Notes | |||||||||||||||||
| Convertible Bridge Loans | |||||||||||||||||
| Total convertible debt | |||||||||||||||||
| Convertible promissory notes, due to related parties | |||||||||||||||||
| Bridge loans | |||||||||||||||||
| Related party loans | |||||||||||||||||
| Revolving line of credit | |||||||||||||||||
| Obligation to issue common stock | |||||||||||||||||
| Operating lease liability, current | |||||||||||||||||
| Other current liabilities | |||||||||||||||||
| Income tax payable | |||||||||||||||||
| Convertible promissory note - related party | |||||||||||||||||
| Total current liabilities | |||||||||||||||||
| Derivative warrant liability | |||||||||||||||||
| Deferred underwriting commissions in connection with the initial public offering | |||||||||||||||||
| Related party loans | |||||||||||||||||
| Derivative warrant liabilities | |||||||||||||||||
| Senior convertible promissory notes, due to related parties | |||||||||||||||||
| Operating lease liability, non-current | |||||||||||||||||
| Deferred tax liabilities | |||||||||||||||||
| Total liabilities | |||||||||||||||||
| Common stock subject to possible redemption; 6,083,500 and 17,161,500 shares at redemption value of approximately $10.32 and $10.09 per share as of June 30, 2023 and December 31, 2022, respectively | |||||||||||||||||
| Common stock subject to possible redemption | |||||||||||||||||
| Total common stock subject to possible redemption; 6,083,500 and 17,161,500 shares at redemption value of approximately $10.32 and $10.09 per share as of June 30, 2023 and December 31, 2022, respectively | |||||||||||||||||
| Stockholders’ deficit: | |||||||||||||||||
| Common stock, $0.0001 par value; 500,000,000 authorized shares as of March 31, 2025 and December 31, 2024; 51,306,712 and 44,238,754 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | |||||||||||||||||
| Common stock not subject to possible redemption | |||||||||||||||||
| Total common stock, $0.0001 par value; 500,000,000 authorized shares as of March 31, 2025 and December 31, 2024; 51,306,712 and 44,238,754 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | |||||||||||||||||
| Additional paid-in capital | |||||||||||||||||
| Subscription receivable | |||||||||||||||||
| Receivable from shareholder | |||||||||||||||||
| Accumulated deficit | |||||||||||||||||
| Total stockholders’ deficit | |||||||||||||||||
| Total liabilities and stockholders’ deficit | |||||||||||||||||
Loading...
